Eptifab 0.75mg Injection

Eptifab 0.75mg Injection

Drug Name:

Eptifab 0.75mg Injection

Category:

International Brand: Eptifab

Eptifab

Details

Drug name: Eptifibatide
Category: Antiplatelet / Cardiology
International Brand Name: Integrilin
Available Strength: 0.75 mg

Uses:

  • Prevents blood clots in patients undergoing angioplasty or other cardiac procedures
  • Reduces the risk of heart attacks in patients with acute coronary syndrome (ACS)
  • Used in combination with aspirin and heparin to enhance clot prevention
  • Helps stabilize patients with unstable angina or non-Q-wave myocardial infarction
  • Supports improved outcomes during percutaneous coronary interventions (PCI)

How it works

Eptifab contains eptifibatide, a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation. By preventing platelets from sticking together, it reduces the formation of harmful clots in blood vessels. This targeted action ensures smooth blood flow, especially during critical heart procedures.

Dosage

Administered intravenously under strict medical supervision. The typical regimen includes a bolus injection followed by a continuous infusion. Dosage may vary based on body weight and clinical indication.

Side Effects:

  • Bleeding at the injection site or internally
  • Low platelet count (thrombocytopenia)
  • Nausea or dizziness
  • Mild to moderate hypotension
  • Headache or back pain

Precautions:

  • Regularly monitor platelet levels and bleeding parameters
  • Patients who have undergone recent surgical procedures or experienced physical injury should be carefully assessed before administering this medication.
  • Ensure hydration and renal function monitoring in elderly patients
  • Not advised for use alongside other strong anticoagulants without medical guidance
  • Avoid abrupt discontinuation during procedures

Contraindications:

  • Active internal bleeding or recent stroke
  • Severe uncontrolled hypertension
  • Thrombocytopenia or bleeding disorders
  • Hypersensitivity to eptifibatide or related compounds
  • Any individual who has had significant surgery or sustained serious injury within the last six weeks may not be suitable for this treatment.

Interactions:

  • Potentiates the effects of anticoagulants like heparin or warfarin
  • Increased bleeding risk with NSAIDs or aspirin
  • Should not be combined with other GPIIb/IIIa inhibitors
  • Interaction possible with thrombolytic agents
  • Close monitoring required with antiplatelet drugs like clopidogrel